CRS-HIPEC: A Hopeful Breakthrough for Advanced Gastric Cancer with Peritoneal Metastasis

CRS-HIPEC: A Promising Treatment for Advanced Gastric Cancer, or stomach cancer, is a challenging disease, especially when it spreads to the abdominal lining (peritoneum), known as peritoneal metastasis. This advanced stage often has a poor prognosis, with survival typically measured in months. However, a specialized treatment called Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) offers hope for some patients.

What is CRS-HIPEC?

CRS-HIPEC combines two steps. First, surgeons perform cytoreductive surgery to remove all visible tumors from the stomach and abdomen. This meticulous procedure can take hours but aims to leave no detectable cancer behind. Then, during HIPEC, heated chemotherapy drugs (around 107°F) are circulated in the abdominal cavity to kill any remaining microscopic cancer cells. The heat enhances the chemo’s effectiveness, and direct delivery minimizes side effects compared to traditional IV chemotherapy.

Why does it matter?

Recent studies show CRS-HIPEC can significantly extend survival for select gastric cancer patients with peritoneal metastasis, with median survival ranging from 9.8 to 28.2 months compared to 4.9–8 months with standard chemotherapy. It’s particularly effective for younger, healthier patients with limited cancer spread. However, it’s a complex procedure with risks, so it’s typically offered at specialized centers and considered experimental, requiring careful patient selection.

What’s the outlook?

While not a cure, CRS-HIPEC can improve survival and quality of life for some. Ongoing trials are refining its use, aiming to identify ideal candidates. If you or a loved one face advanced gastric cancer, consult a specialist at a high-volume center to explore this option. It’s a beacon of hope in a tough fight!